International: +1-347-960-6455
Hypersomnia Therapeutics - Pipeline Analysis 2018

Hypersomnia Therapeutics - Pipeline Analysis 2018, Clinical Trials & Results, Patents, Designations, Collaborations, and Other Developments

Report Code: PP10101 Report Type: Indication Pipeline Reports Available format: 
Therapeutic Area(s): Neurology
Select License Type

Hypersomnia is a medical condition which is characterized by excessive daytime sleepiness. It is categorized into primary hypersomnia and secondary hypersomnia. People with hypersomnia also suffer from other sleep-related problems, such as clear thinking problems and lack of energy. Some of the most common causes of hypersomnia are sleep apnea, obesity, alcohol abuse, smoking, cardiovascular disorders, kidney diseases, neurological disorders, and depression.

The standard treatments available for hypersomnia are antidepressants, stimulants, and other medications. SK Biopharmaceuticals Co. Ltd. is in the process of developing SKL-N05 as a neurotransmitter modulator for the treatment of hypersomnia. Umecrine Cognition AB is another key player involved in development of drugs for the management of this medical condition.

  • The report provides a comprehensive understanding of the pipeline activities covering all drug candidates under various stages of development, with the detailed analysis of pipeline and clinical trials.
  • Pipeline analysis of drugs by phases includes product description and development activities including information about clinical results, designations, collaborations, licensing, grants, technology, and others.